Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.55 |
| ▸ | PPARA | Q07869 | 12/20 | 0.55 |
| ▸ | PPARD | Q03181 | 6/20 | 0.55 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | MMP14 | P50281 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP10 | P09238 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693382 | 0.95 | PPARG (0.53) | PPARGPPARAPPARDMMP13MMP14 | |
| SCHEMBL14144777 | 0.92 | PPARG (0.54) | PPARGPPARAPPARDMMP13MMP14 | |
| SCHEMBL2804684 | 0.92 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL4693407 | 0.91 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL4692671 | 0.89 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL4694804 | 0.88 | PPARG (0.62) | PPARGPPARAPPARD | |
| SCHEMBL4688870 | 0.84 | PPARG (0.65) | PPARGPPARAPPARDMMP13MMP14 | |
| SCHEMBL4689724 | 0.82 | PPARG (0.81) | PPARGPPARAPPARD | |
| SCHEMBL14145129 | 0.81 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL14144773 | 0.81 | PPARG (0.84) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.